A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Inclusion Criteria
- Inclusion Criteria: Patients may be eligible for inclusion in the study if they meet the following criteria: 1. Histologically proven LGSOC (ovarian, fallopian, peritoneal) 2. Documented mutational status of KRAS by a validated tumor-tissue based diagnostic test. 3. Suitable for treatment with at least one of the Investigator's Choice of Treatments:pegylated liposomal doxorubicin, paclitaxel, letrozole, anastrozole. 4. Progression or recurrence of LGSOC after at least one prior systemic therapy for metastatic disease. 5. Measurable disease according to RECIST v1.1. 6. An Eastern Cooperative Group (ECOG) performance status ≤ 1. 7. Adequate organ function. 8. Adequate recovery from toxicities related to prior treatments. 9. For patients with reproductive potential, a negative pregnancy test must be confirmed and agreement to use highly effective method of contraceptive. 10. Willingness to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures. Exclusion Criteria: Patients will be excluded from the study if they meet any of the following criteria: 1. Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy. 2. Co-existing high-grade serous ovarian cancer or mixed histology. 3. Prior treatment with avutometinib, defactinib, or other FAK inhibitors. 4. History of prior malignancy with recurrence <3 years from the time of enrollment. 5. Major surgery within 4 weeks, minor surgery within 1 week, or palliative radiotherapy within 1 week of the first dose of study intervention. 6. Symptomatic brain metastases requiring steroids or other interventions, known leptomeningeal metastases, or spinal cord compression. 7. An active skin disorder that has required systemic therapy within one year of the first dose of study intervention. 8. History of medically significant rhabdomyolysis. 9. For subjects with prior MEK or RAF exposure, Grade 4 toxicity is deemed related to the MEK inhibitor. 10. Symptomatic bowel obstruction within 3 months of the first dose of study intervention 11. Concurrent ocular disorders. 12. Concurrent heart disease or severe obstructive pulmonary disease. 13. Active or past medical history of interstitial lung disease/pneumonitis, including drug-induced or radiation pneumonitis, pulmonary fibrosis, or adult respiratory distress syndrome (ARDS). 14. Subjects with the inability to swallow oral medications. 15. History of hypersensitivity to any of the active agents or ingredients of study intervention: peanut, soya, polyoxyl castor oil, etcetc.). Prior hypersensitivity to anthracyclines or anthracenediones if the use of pegylated liposomal doxorubicin (PLD) is planned. 16. Pregnant or breastfeeding. 17. Active, uncontrolled infection (bacterial, viral, or fungal) requiring systemic therapy.
Additional locations may be listed on ClinicalTrials.gov for NCT06072781.
Locations matching your search criteria
United States
California
Los Angeles
San Francisco
Connecticut
New Haven
Florida
Tampa
Georgia
Atlanta
Maryland
Baltimore
Missouri
Saint Louis
New York
Buffalo
New York
North Carolina
Charlotte
Ohio
Cleveland
Columbus
Oklahoma
Oklahoma City
Pennsylvania
Willow Grove
Texas
Houston
Virginia
Charlottesville
This international, randomized, open-label, Phase 3 study will compare the
investigational combination of avutometinib plus defactinib versus Investigator's Choice
of Treatments (ICT) in patients with recurrent LGSOC who have progressed on a prior
platinum-based therapy. Avutometinib and defactinib are both types of drugs called kinase
inhibitors. Kinase inhibitors block cancer cell growth. The study will compare the
progression-free survival (PFS) of the combination of avutometinib plus defactinib versus
ICT. The study will also evaluate the effect of the combination on safety, overall
survival, other efficacy endpoints, and health-related quality of life and disease
related symptoms. The study is being conducted by gynecological cancer specialists.
Patients who are eligible and agree to participate in this study will be treated with
either a combination of avutometinib with defactinib, or with one of four standard of
care NCCN and ESMO treatment recommendations for recurrent LGSOC, and then with
subsequent follow up appointments. Patients who originally received one of the standards
of care treatments who are determined to have progressive disease may be eligible to
crossover to receive the investigational combination avutometinib plus
defactinib.Avutometinib and defactinib are investigational drugs that have not been
approved by the U.S. Food and Drug Administration (FDA)
Trial PhasePhase III
Trial Typetreatment
Lead OrganizationVerastem Inc
Principal InvestigatorRachel Nicole Grisham
- Primary IDVS-6766-301
- Secondary IDsNCI-2024-00300, ENGOT-ov81, GOG-3097
- ClinicalTrials.gov IDNCT06072781